Abraxane nab-paclitaxel regulatory update

The U.K.’s NICE issued a final appraisal determination (FAD) recommending against the use of Abraxane nab-paclitaxel from Celgene for first-line treatment of metastatic pancreatic cancer in combination with gemcitabine -- 1 of its approved indications in the EU. The FAD is in line with a preliminary appraisal (see BioCentury, Sept. 15, 2014). Celgene is appealing the FAD; an appeal panel is scheduled for March 16. ...